(800) 943-6396

150 Essex St, Millburn, NJ 07041, USA

©2019 by Bon Opus Biosciences, LLC.

MLH1 Recombinant Rabbit monoclonal Antibody IgG

SKU: BA111402-100µl
$279.00Price
 
  
  
 
    
Fig1: Western blot analysis of MLH1 on A431 cells lysates using anti-MLH1 antibody at 1/1,000 dilution.
 
Fig2: ICC staining MLH1 in HepG2 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
 
Fig3: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-MLH1 antibody. Counter stained with hematoxylin.
 		 
  
 
 

 Bon Opus Cat. #BA111402
Size
100 µl

  • Host Species; Species Reactivity

    Rabbit; Human, Mouse, Rat

  • Immunogen

    Recombinant protein

  • Application Summary

    WB, ICC/IF, IHC, IP, FC

  • Purification; Formulation

    ProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.

  • ALTnames

    DNA mismatch repair protein Mlh1, MutL protein homolog 1

  • Background

    DNA-mismatch repair (MMR) is an essential process in maintaining genetic stability. Lack of a functional DNA-mismatch repair pathway is a common characteristic of several different types of human cancers, either due to an MMR gene mutation or promoter methylation gene silencing. MLH1 is an integral part of the protein complex responsible for mismatch repair and is expressed in lymphocytes, heart, colon, breast, lung, spleen, testis, prostate, thyroid and gall bladder tissues, and is methylated in several ovarian tumors. Loss of MLH1 protein expression is associated with a mutated phenotype, microsatellite instability and a predisposition to cancer. In hereditary nonpolyposis colorectal cancer (HNPCC), an autosomal dominant inherited cancer syndrome that signifies a high risk of colorectal and various other types of cancer, the MLH1 gene exhibits a pathogenic mutation. Certain cancer cell lines, including leukemia CCRF-CEM, colon HCT 116 and KM12, and ovarian cancers SK-OV-3 and IGROV-1, show complete deficiency of MLH1, while MLH1 is expressed in 60% of melanomas, 70% of noninvasive squamous cell carcinomas and 30% of invasive squamous cell carcinomas.(ET1604-41)